GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » 3-Year EBITDA Growth Rate

PODD (Insulet) 3-Year EBITDA Growth Rate : 41.20% (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Insulet 3-Year EBITDA Growth Rate?

Insulet's EBITDA per Share for the three months ended in Mar. 2025 was $1.07.

During the past 12 months, Insulet's average EBITDA Per Share Growth Rate was 21.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 41.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 34.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Insulet was 262.50% per year. The lowest was -15.90% per year. And the median was 35.60% per year.


Competitive Comparison of Insulet's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Insulet's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Insulet's 3-Year EBITDA Growth Rate falls into.


;
;

Insulet 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Insulet  (NAS:PODD) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Insulet 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Insulet's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Executives
John W. Kapples officer: SVP, Secretary and GC C/O GCP APPLIED TECHNOLOGIES INC., 62 WHITTEMORE AVENUE, CAMBRIDGE MA 02140
Eric Benjamin officer: SVP, R&D, New Prod Dev. & Comm C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Lauren Budden officer: VP, CAO and Controller C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720